ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO641

Demographic, Clinical Characteristics, and Treatment Outcomes of C3 Glomerulopathy in China: A Nationwide Retrospective Cohort Study

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Nie, Sheng, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
  • Zhou, Shiyu, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
  • Gao, Qi, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
  • Li, Ping, Beijing Novartis Pharma Ltd, Beijing, China
  • Gao, Fei, Beijing Novartis Pharma Ltd, Beijing, China
  • Zhang, Shaosen, Beijing Novartis Pharma Ltd, Beijing, China

As a rare glomerular disease, there is limited data on the demographic, clinical characteristics, and treatment outcomes of C3 glomerulopathy (C3G) in China.


Patient medical records were retrospectively collected from 24 regional central hospitals across China, from 2013 to 2021. Descriptive analysis was performed on clinical characteristics, treatment, and outcomes. χ2 test was performed to analyze the difference between children and adult groups.


470,000 patients with chronic kidney disease (CKD) were enrolled, of which 102 patients were C3G confirmed by renal biopsy. Among them, 9 were diagnosed with dense deposit disease and 93 were diagnosed with C3 glomerulonephritis. At the time of diagnosis, 46.2% of C3G patients had an eGFR<60 ml/min/1.73m2, 47.1% had low serum complement C3, 48.8% had low serum C4, 22.5% had abnormal blood/urine protein electrophoresis, and 3% had elevated serum globulin. Besides C3 deposition, 4.9% and 12.7% of patients combined IgA and IgG deposition in pathological immunofluorescence, respectively. Compared to children, adult patients tended to present severe symptoms at diagnosis (Table 1). 55 patients (53.9%) received treatment with RASI, while 48 (47.1%) patients received glucocorticoids and 24 patients combined glucocorticoids with other immunosuppressants (cyclosporine, etc.). 16 patients were followed up for more than one year. Among them, 2 patients showed ≥40% decrease in eGFR from baseline, and 3 patients developed end stage renal disease (ESRD) within one year.


C3G has heterogeneous clinical characteristics, and adult patients presented more serious symptoms at diagnosis. Gaps are identified for C3G patients standardized treatment in China, and targeted therapy is urgently needed.

Baseline characteristics of patients with C3G stratified by age.


  • Commercial Support – Beijing Novartis Pharma. Co. Ltd.